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Highlights 
 Oral misoprostol did not hasten oviductal transport of equine embryos  
 Oral misoprostol did not affect serum progesterone concentration  





In horses, prostaglandin E2 (PGE2) is produced by embryos around Day 5 post-ovulation; 
PGE2 functions directly at the oviduct promoting embryo transport into the uterus. Non-











7 post-ovulation. It was proposed that misoprostol administered orally will hasten 
oviductal transport of horse embryos. In Experiment 1 (n = 15) there was comparison of 
time of embryo recovery (Day 6 and 6.5 post-ovulation) from mares administered 
misoprostol (Day 5 and 5.5) orally to that of untreated mares. On Day 6, embryo 
collections were attempted; if no embryo was collected, there was a second attempt on 
Day 6.5. In Experiment 2, (n = 16) misoprostol treatment was initiated on Day 4.5; there 
was the first embryo collection attempt on Day 5.5, followed by Day 6 and 6.5 if no embryo 
was collected. Blood samples were collected at 12 h intervals on Day 4.5 or 5, to Day 6.5. 
In Experiment 1, on days 6 and 6.5, respectively, there was collection of seven and one 
of a total of eight embryos detected at the time of collection per group (P = 1). In 
Experiment 2, 12 embryos were collected during 15 cycles with there being a total of 
three, two, and one collected from mares of both groups on Day 5.5, 6, and 6.5 post-
ovulation, respectively (P = 1). Serum progesterone concentrations were not different (P 
≥ 0.05). In conclusion, misoprostol, when administered orally, does not hasten oviductal 
transport of horse embryos. 
 












In most mammals, embryos and oocytes are transported to the uterus. In mares, 
embryos, but not unfertilized oocytes, are selectively transported to the uterus (Betteridge 
and Mitchell, 1974). This selective mechanism has important implications for the embryo 
transfer industry. 
The non-surgical collection of small embryos (<300 microns) requires that the 
uterine lavage occurs at 6 to 7 days post-ovulation. On Day 7 and later, the mean 
diameter of the embryo is >300 microns (Vanderwall, 2000; McCue et al., 2010). Reported 
pregnancy rates when there is transfer of small embryos into recipient females after 
cryopreservation can be as great as 70%. When there is transfer of expanded blastocysts 
(>300 microns) into recipient mares, there is only 10% to 20% pregnancy rate if there has 
been cryopreservation of these embryos using traditional methods (reviewed in Allen, 
2001; McKinnon and Squires, 2009). There is need for use of more advanced techniques 
for blastocoel collapse before vitrification if pregnancy rates resulting from embryo 
transfer are going to be similar to those when there is transfer of small embryos (Checura 
and Parrish, 2006; Seidel Jr. et al., 2010; Troedsson et al., 2010; Squires and McCue, 
2016).  
Non-surgical embryo recovery rates for Days 7, 8, and 9 following ovulation are 
similar, while the recovery rate on Day 6 is less. This lesser embryo recovery rate may 
be attributed to failure of 1) some embryos to be transported into the uterus by Day 6, 2) 
to collect embryos when the procedure for collection is conducted, or 3) accurate 
determination of time of ovulation. In some studies, mares from which there was failure 











(reviewed in Vanderwall, 2000; Allen, 2001; McKinnon and Squires, 2009; Squires and 
McCue, 2016). Based on results form a study from Freeman et al. (1991), some embryos 
are transported into the uterus after Day 6, and therefore, embryo recovery rates on Day 
6.5 should be greater than when there are attempts to collect embryos on Day 5.9 or 
earlier subsequent to ovulation.  
There is a clear function of prostaglandin E2 (PGE2) on the oviductal transport of 
horse embryos. There are relatively greater concentrations of PGE2 by Day-5 and -6 
subsequent to ovulation and this secretion is temporally associated with PGE2-specific 
binding to the oviductal wall of mares and with the oviductal transport of the embryo 
(Weber et al., 1991b; Weber et al., 1992). In addition, the administration of a continuous 
intra-oviductal infusion of PGE2 resulted in a markedly accelerated transport of embryos 
in more mares compared to when the administration with a continuous intra-oviductal 
infusion of vehicle or no treatment administration. Oviductal transport, however, was 
apparently not hastened after intramuscular, intrauterine, or intraperitoneal PGE2 
administration to inseminated mares (Weber et al., 1991a). Laparoscopic administration 
of PGE2 directly on the oviductal surface was effective leading to an increased embryo 
collection rate on Day 5 (reviewed in Allen, 2001). Surgical administration of PGE2, 
however, is expensive and impractical for the sole purpose of recovering small embryos 
for cryopreservation. 
Misoprostol is a synthetic prostaglandin E1 analog that interacts with E-prostanol 
(EP) receptors EP2, EP3, and EP4 (Blikslager et al., 2001). In horses, misoprostol is 
indicated for the treatment of right dorsal ulcerative colitis associated with non-steroidal 










gastroenteropathies (Lopp et al., 2019; Martin et al., 2019). In addition to the 
gastrointestinal protective applications of misoprostol; it is  administered to women as a 
cervical-softening agent, for abortion in early pregnancy, induction of labor, and 
augmentation of uterine contractions when there is need for treatment of serious 
postpartum hemorrhage (Zhang et al., 2015; Bilgin and Komurcu, 2019). Conversely, 
when misoprostol was administered orally, there were no adverse effects when there was 
treatment of pregnant mares during early (Linton and McDonnell, 2014) or mid-gestation 
(Jacobson et al., 2013). Furthermore, the intra-cervical administration of PGE2 for 
induction of cervical relaxation in mares (Nie and Barnes, 2003; LeBlanc, 2006) is 
controversial (McNaughten et al., 2014). There is intra-uterine administration of 
misoprostol directly onto the oviductal papilla for the treatment of presumptive blockage 
of the oviducts (Alvarenga and Segabinazzi, 2018). Misoprostol, therefore, has the 
potential to stimulate PGE2 oviductal receptors and hasten oviductal transport of early-
developing embryos into the uterus. 
Prostaglandin E2 has an important function in the ovulatory cascade and 
luteinization of follicular cells (reviewed in Checura, 2015). The effects of PGE2 in 
progesterone production of the corpus luteum are complex. Treatment with PGE2 resulted 
in increased secretions of both progesterone and prostaglandin F2α (PGF2α) from cultured 
luteal cells of cattle (Del Vecchio et al., 1995) but treatment with PGE2 also induces a 
reduction in receptors for both PGE2 and PGF2α (Weems et al., 2012). Systemic 












Timing recoveries of embryos at Day 6.5  following ovulation entails assessing the 
mares twice a day for estimating the time of ovulation. These procedures are easy to 
accomplish in referral centers with a mare on site, but there are problems with logistic, 
management of mares, and increased expenses for small scale breeders and ambulatory 
veterinary practitioners. To collect small embryos when mares are assessed once a day 
for estimating the time of ovulation, the recovery of the embryo should occur 6 days after 
ovulation is detected. Increasing the recovery rate of small embryos at the time of uterine 
flushing on Day 6 with use of a simple and relatively inexpensive process will make 
cryopreservation more efficient and widely used in mares (Squires and McCue, 2016). It 
was hypothesized that oral administration of misoprostol could be an alternative to PGE2 
administrations directly on the oviduct to hasten oviductal transport of horse embryos at 
the Day-5 developmental stage.  
 
2. Materials and methods 
2.1. Animal use and care protocols 
Animal use and care protocols were reviewed and approved by the University of 
Wisconsin-Madison Institutional Animal Care and Use Committee for Experiment 1, 
Animal Use Protocol number V005218; and by the Comité de Ética at the Universidad 
Nacional de Río Cuarto for Experiment 2, number 207/18-FAV-UNRC.  
 
2.2. Experiment 1 
The objectives for Experiment 1 were to compare the time at which the embryo 










of oral misoprostol compared with untreated control mares, and to determine effects of 
misoprostol when administered orally on serum progesterone concentrations at days 5 to 
6.5 post-ovulation. 
 
2.2.1. Animals and procedures 
Fifteen estrous cycling mares of mixed light breeds, 3 to 17 years of age, were 
assigned for use in Experiment 1. All mares were examined by a board certified 
theriogenologist at the beginning of the experiment and were considered reproductively 
sound. Mares were located in Madison, WI, USA (43°04'29.5"N 89°25'09.2"W) and the 
data were collected during two breeding seasons. Following detection of endometrial 
edema and a preovulatory (>35 mm) follicle, ovarian functions were monitored every 12 
h and mares were artificially inseminated with ≥ 0.5 x 109 motile spermatozoa every other 
day until ovulation (ovulation day = Day 0). Ovulation was detected by ultrasonography 
to have occurred when the preovulatory follicle present at the previous ultrasound 
examination was observed to have evacuated >90% of its follicular fluid (Ginther, 1995). 
Inseminated mares were randomly assigned to not be treated (untreated control group) 
or to be treated with misoprostol. Misoprostol (Gavis Pharmaceuticals, Somerset, NJ, 
USA) was administered orally at 0.009 mg/kg BW, on Days 5 and 5.5. On Day 6, standard 
non-surgical embryo recovery procedures were conducted (see section 2.3) utilizing two 
liters of embryo recovery media (Vigro™ Complete Flush Solution, Vetoquinol USA, Inc., 
Fort Worth, TX, USA) to flush the uterus in an attempt to collect the embryos. If an embryo 
was not collected on Day 6, there was a second attempt at collection on Day 6.5. The 











point for the statistical analysis; therefore, data were only included in the statistical 
analyses if there were embryos collected from mares after the procedures for both the 
treatment and control experimental regimens had been imposed. After the initial 
randomized assignment, mares were assigned to alternate experimental groups until an 
embryo was recovered, then the mare was assigned to the other group until the second 
embryo was recovered. When there were unilateral double ovulations in a mare, the data 
were excluded from the analyses. Blood samples were collected from the jugular vein at 
12 h intervals on Day 5 to 6.5. On Day 6.5, all mares were administered PGF2α (10 mg 
dinoprost tromethamine – Lutalyse, Zoetis, Parsippany, NJ, USA – intramuscular). 
 
2.3. Experiment 2 
The objectives for Experiment 2 were to compare the time at which the embryo 
was recovered (Day 5.5 or Day 6 or 6.5 following ovulation) from mares treated twice with 
an oral dose of misoprostol compared with mares not administered misoprostol, and to 
determine the effect of oral misoprostol on serum progesterone concentrations and 
corpus luteum echogenic characteristics at days 4.5 to 6.5 following the time when 
ovulation was detected to have occurred. 
 
2.3.2.  Animals and procedures 
Estrous cycling mares of mixed light breeds (n = 16), 2.5 to 15 years of age, were 
assigned for use in Experiment 2. All mares were examined by a board certified 
theriogenologist at the beginning of the experiment and were considered reproductively 











64°18'06.7"W) and the data were collected for a period of 30 days during the breeding 
season. Following detection of endometrial edema and a preovulatory (>35 mm) ovarian 
follicle, ovarian activity was monitored every 12 h using ultrasonic procedures and mares 
were artificially inseminated with 1 x 109 motile spermatozoa every other day until 
ovulation (ovulation day = Day 0). Ovulation was detected by ultrasonography to have 
occurred when the preovulatory follicle present at the previous ultrasound examination 
was observed to have evacuated >90% of its follicular fluid (Ginther, 1995). Inseminated 
mares were alternately assigned to a treatment group at the time when ovulation was 
detected to have occurred (untreated control or misoprostol treatment: 0.009 mg/kg, per 
os, two doses 12 h apart), and all treatments were administered starting on Day 4.5. On 
Day 5.5, standard non-surgical procedures were conducted using 2 liters of embryo 
recovery media (Lactate ringer solution – 624-L, Rivero laboratories, Ciudad Autónoma 
de Buenos Aires, Argentina – with 0.01% polyvinyl alcohol – P-8136 Sigma-Aldrich, Saint 
Louis, MO, USA) to flush the uterus in an attempt to collect embryos, and whether there 
was an embryo collected or not collected was recorded. If an embryo was not collected, 
there was a second attempt at embryo collection on Day 6, and again, if an embryo was 
not recovered on Day 6, a third attempt at embryo collection occurred on Day 6.5. After 
the initial randomized assignment, mares were assigned to the alternate treatment group 
for conducting the other experimental regimen. Each estrous cycle was considered as an 
independent variable for statistical purposes and the time at which the embryo was 
collected was the end-point value recorded for the variable when conducting the statistical 
analysis. Data, therefore, from an estrous cycle were only included for statistical analyses 











was a unilateral double ovulation that occurred were excluded from the statistical 
analyses. Blood samples were collected from the jugular vein at 12 h intervals from Days 
4.5 to 6.5 subsequent to the time ovulation was detected to have occurred. The B-Mode 
ultrasonic images of the corpus luteum were collected at 12 h intervals from Days 4.5 to 
6.5 after ovulation was detected to have occurred. On Day 6.5, all mares were 
administered PGF2α (10 mg Dinoprost tromethamine – Lutalyse, Zoetis, Parsippany, NJ, 
USA –, intramuscular).  
 
2.3.3. Ultrasonic images  
Ultrasonic images were analyzed using ImageJ (National Institute of Health, 
Bethesda, MD, USA). To determine average pixel area and pixel intensity, the outer edge 
of the corpus luteum was delineated by an operator in each image and a pixel histogram 
analysis was conducted.  Each image was delineated and analyzed three times and the 
averages for pixel area (number of pixels) and pixel intensity (scale 0 to 255, where 0 is 
black and 255 is white) were used for statistical analysis.  
 
2.4.  Embryo recovery procedure 
For embryo recovery, the mare was placed in stocks, the tail wrapped, the perineal 
area cleaned and dried. A silicone balloon-tipped catheter (86 cm, 32 Fr, 75 cc balloon, 
Bioniche Animal Health, ON, Canada) was passed through the cervix into the uterine 
body. Sterile sleeve and sterile lubricant were used by the operator to manually insert the 
catheter into the uterine body. The balloon-cuff was inflated with approximately 30 to 60 











cervical os. The uterus was filled and emptied ("flushed") three to four times with a total 
of 2 liters of embryo recovery solution (Experiment 1: Vigro™ Complete Flush Solution, 
Vetoquinol USA, Inc., Fort Worth, TX, USA; Experiment 2: Lactate ringer solution – 624-
L, Rivero laboratories, Ciudad Autónoma de Buenos Aires, Argentina – with 0.01% 
polyvinyl alcohol – P-8136 Sigma-Aldrich, Saint Louis, MO, USA).  Massage of the uterus 
per rectum and manipulation of the catheter was conducted to distribute the fluid in both 
uterine horns and to facilitate fluid recovery. The recovered fluid was filtered (Em-ConTM -
0.75 µm- Immuno Systems, Spring Valley, WI, USA, or EmSafe -0.65 µm- filters Minitube 
USA, Verona, WI, USA) and there were observations for embryos in the fluid using a 
stereomicroscope (Vanderwall, 2000). 
 
2.5.  Serum progesterone samples 
 Blood samples were centrifuged immediately after collection and serum was stored 
at -20 ºC until hormone assays were conducted. All serum progesterone concentrations 
were determined using a radioimmunoassay with I125 at a commercial laboratory in the 
USA (BET Laboratories, Lexington, KY, USA): Progesterone CT kits (MP Biomedicals 
LLC, Irvine, CA, USA) were used; the standard curve was based on seven standards 
analyzed at the same time as the samples; four control samples 0.1, 1.0, 5.0, and 20.0 
ng/ml used to ascertain hormone recovery values when the assays were conducted and 
CV's were less than 10%. All samples, including standards, were analyzed in duplicate.  
 











Serum progesterone and pixel data were analyzed as repeated measures over 
time using the mixed procedure in the Statistical Analysis System software (SAS Institute, 
Cary, NC, USA). Time and treatment were considered to be fixed effects and mare-within-
treatment was a random effect. The interaction of treatment by time was included in the 
model. For the repeated measures analysis, the first order autoregressive covariance 
structure (AR1) was used to fit a time series-type covariance structure in which the 
correlation decreases as a function of time. Normality of distribution for the data was 
tested using the univariate procedure in SAS, with emphasis on the residual plot, the 
Sharpiro-Wilk and the Kolmogorov-Smirnov tests. There were considered to be 
differences in mean values when there was a P ≤ 0.05 and there was considered to be a 
tendency for differences when there was a 0.05 < P <0.10 value.  
   
3. Results 
3.1.  Experiment 1 
Of the 15 mares in this experiment, there was only detection of an embryo in the 
flushing solution of eight mares in both experimental groups. Reasons for exclusion of 
data were: detection of a double ovulation, fluid in the uterus at the time of embryo 
recovery, mare being removed from the herd before two embryos were recovered, 
recovering an embryo when there was one experimental regimen imposed, however, not 
when the other experimental regimen was imposed (treatment or control), and failure to 
detect an embryo after flushing the mare uterus. For both groups, seven of eight embryos 
were collected on Day 6 and the remaining embryo was collected on Day 6.5 (different 











recovery in each group were identical, a statistical analysis was not performed (P = 1). 
All embryos were ≤ 300 microns in diameter. Serum progesterone concentration data 
were normally distributed. Serum progesterone concentrations were not different (P ≥ 
0.05) for the mares of the control compared with the misoprostol groups (12.5 ± 1.3 ng/ml 
and 11.8 ± 1.2 ng/ml, respectively; LSM ± SEM) and there was no effect (P ≥ 0.05) of 
time or treatment-by-time interaction (data not shown). 
 
3.2.  Experiment 2 
 There were evaluations during seventeen estrous cycles for this experiment; 
during two estrous cycles, there were unilateral double ovulations, therefore, data from 
these mares were excluded when there were statistical analyses. Of the remaining 15 
estrous cycles during which data were collected, during 12 of these estrous cycles, there 
was collection of embryos with data being included in the statistical analyses: n = 6 for 
each experimental group. The distribution of Day of embryo recovery was Day 5.5 = three 
estrous cycles, Day 6 = two estrous cycles, and Day 6.5 = one estrous cycle with there 
again being the same pattern for mares in both the control and misoprostol-treatment 
groups (Fig. 1.). A statistical analysis was not performed because the data sets were 
identical (P = 1). All embryos were ≤ 300 microns in diameter. 
Serum progesterone concentration data were normally distributed. Serum 
progesterone concentrations were not different (P ≥ 0.05) for control and misoprostol-
treated mares (20.0 ± 2.8 ng/ml and 15.2 ± 2.5 ng/ml, respectively; LSM ± SEM), there 











Corpus luteum pixel area data were normally distributed. Corpus luteum pixel 
areas were not different (P ≥ 0.05) for the mares of the control or misoprostol-treated 
group (27,660 ± 3,330 pixels and 34,635 ± 3,044 pixels, respectively; LSM ± SEM). There 
was an effect of time (P ≤ 0.05), however, there was not a treatment-by-time interaction 
(P ≥ 0.05; Fig. 3.). 
Corpus luteum pixel intensity data were normally distributed. Average corpus 
luteum pixel intensity was not different (P ≥ 0.05) for the mares of the control and 
misoprostol-treatment group (58.1 ± 3.3 and 58.1 ± 3.0, respectively; LSM ± SEM). There 
was also no effect of time nor was there a treatment-by-time interaction (P ≥ 0.05; Fig. 
3.). 
 
4.  Discussion 
Increasing the collection rate of small Day 6 embryos, combined with vitrification 
techniques, which do not require sophisticated equipment, would allow more practitioners 
to cryopreserve embryos in the field, and therefore, more horse owners to access and 
utilize this technology (Squires and McCue, 2016). In the present study, there was for 
Experiment 1 the hypothesis that the two doses of misoprostol would complement the 
PGE2 being produced by the embryo, and thus hasten embryo transport into the uterus. 
A greater number of embryos collected from the mares of misoprostol-treatment as 
compared with control group was expected for Day 6. Due to the equal number of 
embryos collected on Day 6 in both groups (seven of eight embryos), there was not 
acceptance or rejection of the hypothesis that misoprostol hastens oviductal transport of 











al. (1991) that some embryos may not have been transported into the uterus by Day 6 
subsequent to ovulation. Experiment 2 was designed to increase the distribution of 
possible embryo recovery days to test this hypothesis. In addition, the change in physical 
location of the mares also was associated with a difference in the genetic composition of 
mares and stallions used to conduct Experiment 2. Results from the present study are 
again, as with Experiment 1, consistent with those of Freeman et al. (1991) because half 
of the embryos were collected on Day 5.5 and most of the embryos were collected by 
Day 6 (10 out of 12 embryos), and there was collection of the other two embryos at Day 
6.5 subsequent to the time ovulation was detected (Fig. 1.). In the present study, however, 
there was not any difference in the distribution of times of embryo collections among 
mares of the control and misoprostol-treatment groups. The lack of collections of embryos 
at an earlier time from mares of the misoprostol-treatment group likely indicates that there 
was no effect when misoprostol was administered orally at the dose used in the present 
study on oviductal embryo transport.  
There are several possible reasons for the lack of an effect of misoprostol in the 
present study, including 1) too small a dosage, 2) lack of an efficacious timing of the 
frequency or route of misoprostol administration; 3) a lack of binding of misoprostol to 
and/or adequate populations of PGE2 receptors in the oviduct for binding of misoprostol; 
and 4) a pharmacological downregulation of PGE2 receptors.  
In horses, the effects of oral misoprostol (0.005 mg/kg) on basal free acid contents 
of the stomach lasted for the 8 hours monitored in a previous experiment (Sangiah et al., 
1989). The same dose of misoprostol when administered orally had a half-life of 40 











119 to almost 200 minutes (Lopp et al., 2019). If there had been a greater frequency of 
oral administration of misoprostol, there may have been an effect on enhancing the rate 
of oviductal transport of the horse embryos in the present experiments. It, however, is 
possible that the oviductal misoprostol concentration that is needed for an induction of 
the effects to enhance the rate of horse embryo transport into the uterus cannot be safely 
attained with a systemic dosage, similar to that reported for PGE2, where local 
administration, but not intramuscular, intrauterine, or intraperitoneal administration,  
resulted in an enhanced rate of embryo transport into the uterus from the oviduct (Weber 
et al., 1991a). 
In humans, PGE2 has different effects on the circular and longitudinal muscle 
layers of the oviduct, inhibiting the circular and stimulating the longitudinal musculature in 
vitro (Lindblom et al., 1978). In horses, PGE2 treatment increased electrical activity of the 
oviductal musculature in vivo (Troedsson et al., 1995), and relaxation of the circular 
muscle layer in vitro (Weber et al., 1995). Prostaglandin E2 functions through one of four 
receptors, EP1; EP2; EP3; EP4; signaling via cAMP (EP2 and EP4 receptors) or changes 
in intracellular Ca (EP1 receptors) concentrations. Furthermore, EP3 receptors have 
several splice variants, which may signal via cAMP or changes in intracellular Ca 
concentrations; and there may be synergistic regulations as a result of activation of 
different EP receptors (Blikslager et al., 2001; Blikslager, 2013). In general, activation of 
EP2 and EP4 receptors induces smooth muscle relaxation, whereas activation of EP1 
and EP3 receptors induces smooth muscle contraction. In the horse oviduct, localization 
of the EP2 and EP4 receptors in ciliated epithelial cells, secretory epithelial cells, putative 











additional effects beyond muscular contraction and relaxation (Ball et al., 2013). In 
particular, modulation of ciliary beat and epithelial secretions may also contribute to the 
PGE2-stimulated oviductal transport of the early developing embryo. Misoprostol is a 
PGE1 analog that binds to EP2; EP3; and EP4 receptors (Blikslager et al., 2001) and 
mimics many of the PGE2 effects. Horses, however, may have a different receptor 
interaction with misoprostol than other species. Misoprostol induces early abortions and 
uterine contractility in humans (Zhang et al. 2015; Bilgin and Komurcu, 2019), but it has 
no adverse effects in pregnant mares (Jacobson et al. 2013; Linton and McDonnell, 
2014), and its effects when administered locally in substitution for PGE2 for cervical 
relaxation is controversial (McNaughten et al., 2014). Blikslager (2013) hypothesized that 
a variant of the EP3 receptor with low-affinity and of unknown relevance in myometrial 
cells, may be …“the mechanism whereby misoprostol has less of an effect on contraction 
of urogenital smooth muscle as compared with PGE2”… (Blikslager, 2013). This proposed 
less than optimal (or absent) activation of the EP3 receptor for contractility of the 
muscularis when misoprostol is administered may very well be the reason why there was 
not an enhanced oviductal embryo transport when the conditions of the current 
experiments were imposed.  
An alternative hypothesis as to why there were not effects of the misoprostol 
treatment is the downregulation of PGE2 receptors as a result of administration of 
misoprostol. Large doses of PGE2 downregulate receptors for this prostaglandin in the 
corpus luteum of cattle when there is treatment with intra-luteal implants containing the 











misoprostol at the dose and frequency administered in the present study will result in 
inhibition of contractile functions of the oviduct.  
Prostaglandin E2 is a known luteotropic factor in different domestic species 
because when administered there is a resulting stimulation of progesterone production 
by luteal cells in vitro. Conversely, PGF2α is the primary luteolytic factor, and it is 
predominantly secreted by the endometrium (Del Vecchio et al., 1995; Ferreira-Dias et 
al., 2006; Weems et al., 2012). The enzymes PGE2-9-ketoreductase (9k-PGR) and 
aldoketoreductase (AKR1B5) can have functions in conversion of PGE2 to PGF2α or vice 
versa, and this may be a common occurrence in the horse corpus luteum (Ferreira-Dias 
et al., 2006). Serum progesterone concentrations, corpus luteum pixel area and pixel 
intensity, however, were similar for the mares of the misoprostol-treated and control 
groups in the present study, leading to the conclusion that there was no effect of 
misoprostol on progesterone production and corpus luteum echogenic characteristics 
when the conditions of the current study were imposed.  
There was not an enhanced oviductal transport of horse embryos as a result of 
administration of misoprostol orally in the present study; however, most of the embryos 
from mares in both experiments were recovered at Day 6 or earlier subsequent to the 
time when ovulation was detected to have occurred. Nevertheless, there were a few 
embryos collected on Day 6.5, and there may not be collection of these small embryos 
accomplished when there are once-a-day assessments for time of ovulation occurrence. 
In the present study, there was collection of embryos following a second or even a third 
uterine lavage 12 hours apart. It has been previously reported that 63% of mares from 










embryos collected when there were uterine lavages on day 8 subsequent to the time 
ovulation was detected to have occurred (reviewed in Allen, 2001). Practitioners could 
use this as a strategy to optimize rates of collection for small embryos that are going to 
be cryopreserved by performing embryo collection procedures on Day 6 and repeating 
the lavage on Day 6.5 after the time of detection when ovulation occurred if the first 
attempts at embryo collections were unsuccessful.  
 
5. Conclusion 
Oral administration of misoprostol at the dose used in the present study did not 
enhance the rate of embryo transport from the oviduct into the uterus of mares and does 
not affect progesterone concentration or corpus luteum echogenic characteristics. 
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Fig. 1. Day of embryo recovery for the 12 embryos in Experiment 2; treatment was 
initiated on Day 4.5; untreated control or misoprostol treatment (0.009 mg/kg, per os, 
two doses 12 h apart); first embryo collection attempt was on Day 5.5, if no embryo was 
collected, second attempt on Day 6, third attempt on Day 6.5. Trt: treatment effect. 
 
Fig. 2. Serum progesterone concentration for Experiment 2; treatment was initiated on 
Day 4.5; untreated control (C) or misoprostol (M) (0.009 mg/kg, per os, two doses 12 h 
apart), n = 6 per group; Trt: treatment effect; Time: time effect. 
 
Fig. 3. Ultrasonic-image analysis of the corpus luteum for Experiment 2; treatment was 
initiated on Day 4.5; untreated control (C) or misoprostol treatment (M) (0.009 mg/kg, 
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Control
Misoprostol
Trt: P = 1
Fig. 1. Day of embryo recovery for the 12 embryos in Experi-
ment 2; treatment was initiated on Day 4.5; untreated control
or misoprostol treatment (0.009 mg/kg, per os, two doses 12
h apart); first embryo collection attempt was on Day 5.5, if no 
embryo was collected, second attempt on Day 6, third 































Trt: P ≥ 0.05
Time: P ≤ 0.01
Fig. 2. Serum progesterone concentration for Experiment 2; 
treatment was initiated on Day 4.5; untreated control (C) or
misoprostol (M) (0.009 mg/kg, per os, two doses 12 h apart),









































Fig. 3. Ultrasonic-image analysis of the corpus luteum for
Experiment 2; treatment was initiated on Day 4.5; untrea-
ted control (C) or misoprostol treatment (M) (0.009 mg/kg, 
per os, two doses 12 h apart), n = 6 per group; Trt: treat-
ment effect, Time: time effect.
Trt: P ≥ 0.05
Time: P ≤ 0.05
Trt: P ≥ 0.05
Time: P ≥ 0.05
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